Table 2.
Statistically significant differentially expressed RNAs number in small extracellular vesicles (SEVs) and large extracellular vesicles (LEVs) from patients with Alzheimer's disease (AD), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD) in terms of upregulated transcripts, downregulated transcripts, and total compared with CTRs. Transcripts were considered as differentially expressed when |log2(disease sample/healthy control)|≥1 and an FDR ≤ 0.1.
| AD | FTD | ALS | PD | |||||
|---|---|---|---|---|---|---|---|---|
| SEVs | LEVs | SEVs | LEVs | SEVs | LEVs | SEVs | LEVs | |
| mRNA up-regulated | 0 | 0 | 194 | 64 | 499 | 32 | 0 | 2 |
| mRNA down-regulated | 0 | 0 | 33 | 23 | 43 | 56 | 0 | 10 |
| Total | 0 | 0 | 227 | 87 | 542 | 88 | 0 | 12 |
| lncRNA up-regulated | 0 | 0 | 9 | 9 | 12 | 4 | 0 | 0 |
| lncRNA down-regulated | 0 | 0 | 0 | 2 | 0 | 15 | 0 | 1 |
| Total | 0 | 0 | 9 | 11 | 12 | 19 | 0 | 1 |
AD, Alzheimer's disease; FTD, fronto-temporal dementia; ALS, amyotrophic lateral sclerosis; PD, Parkinson's disease; CTRs, controls; SEVs, small extracellular vesicles; LEVs, large extracellular vesicles; lncRNAs, long non-coding RNAs; FDR, false discovery rate.